Tag Archive for: radioligand therapy
177Lu-PSMA-I&T Results in First Prospective Study
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 1 Trial: 177Lu-NYM032 Shows Efficacy In mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxVIOLET Phase 1/2 Trial Final Results: 161Tb-PSMA-I&T Shows Promising Results
/0 Comments/in Metastatic, Phase 1, Phase 2/by MaxPhase 1/2 Trial of Novel Radioligand Therapy 177Lu-JH020002 Shows Promise
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by Max225Ac-Macropa-PEG4-YS5: a CD46-Targeted 225Ac Therapy for Prostate Cancer
/0 Comments/in Preclinical Research/by MaxUpdate: FC705 Signals a Leap Forward in Prostate Cancer Therapy, Outperforming Pluvicto
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxNew Radiotherapy ATNM-400 Targets Advanced Prostate Cancer
/0 Comments/in Preclinical Research/by MaxPhase 1/2 trial: Novel rhPSMA Therapy Targets Advanced Prostate Cancer With Precision
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxFutureChem Launches Phase 3 Trial for Novel PSMA-Targeted Radiopharmaceutical FC705
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy castration-resistant prostate cancer CDK12 clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology olaparib oncolytic virus personalized medicine prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 23/2025 June 8, 2025
- Protein Design Leaps Forward Thanks to AI June 5, 2025
- Phase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors June 5, 2025
- UPDATE About ACE-232: Phase 1 Trial of a Novel CYP11A1 Inhibitor for mCRPC June 5, 2025